COVID-19 considerations for life sciences M&A
This note sets out some COVID-19 considerations for M&A which are specific to the life sciences sector.
The novel coronavirus and the disease it causes (COVID-19) has caused significant disruption to all businesses around the world but life sciences companies have particularly been thrust into the limelight both in relation to vaccination, treatment or related efforts but also the challenges of continuing to provide healthcare services. This will provide opportunities as well as challenges and it is expected to lead to increased M&A activity in the sector. M&A in the life sciences sector has been more resilient to past recessions than other sectors and this is expected to be the case for the current recession, particularly as it has been directly caused by a health event.
It may take a while for M&A activity to pick up, as businesses are focusing on stabilising and crisis-response in the near term, but the Stephenson Harwood life sciences team is already advising clients in the area.
This note sets out some COVID-19 considerations for M&A which are specific to the life sciences sector.
